Clinical Trial

MLC1501 Study Assessing Efficacy in STROke Recovery

Study acronym: MAEStro
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-09-13; most recent amendment 2023-03-14.
Trial Details
NCT Number NCT05046106
Lead Sponsor Moleac Pte Ltd.
Conditions Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae, Stroke, Cardiovascular, Stroke, Embolic, Stroke, Cryptogenic
Enrollment 540 participants
Start Date 2025-01
Primary Completion 2028-09 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2023-03-16